Comparative Study on in Vitro Effects of Homocysteine Thiolactone and Homocysteine on HUVEC Cells: Evidence for a Stronger Proapoptotic and Proinflammative Homocysteine Thiolactone
Hyperhomocysteinemia is an independent risk factor for the development of atherosclerosis. However the underlying mechanisms responsible for endothelial cell injury with increased plasma concentration of homocysteine or homocysteine derivatives remains still incompletely elucidated. In this study, we investigated the ability of homocysteine (Hcy) and homocysteine thiolactone (HcyT) to induce cell death and IL-8 secretion in primary human umbilical vein endothelial cells (HUVEC). Hcy and HcyT were both cytotoxic and capable of promoting cell death, as measured by caspase-3 activation and DNA fragmentation. ELISA assays clearly demonstrated that Hcy and HcyT strongly activated IL-8 release. Furthermore, our results showed that HcyT was much more efficient than Hcy in activating caspase-3 or in inducing IL-8 secretion. The use of antioxidants such as vitamin C and vitamin E strongly but not completely reduced programmed cell death and chemokine release suggesting that other pathways different than reactive oxygen species are also involved. This study suggests that Homocysteine derivatives like HcyT might possess stronger cytotoxicity and pro-inflammatory properties and that Hcy derivatives levels should therefore be more taken into account during diagnostics.
Keywordshomocysteine thiolactone homocysteine apoptosis proinflammation atherosclerosis antioxidants
human umbilical vein endothelial cells
Unable to display preview. Download preview PDF.
- 1.Wilcken DEL, Dudman NPB: Homocystinuria and atherosclerosis In: AJ Lusis, JI Rotter, RS Sparkes (eds). Molecular Genetics of Coronary Artery Disease; Candidate Genes and Process in Atherosclerosis. Monograms in Human Genetics, Karger, New York, NY, 1992Google Scholar
- 3.Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RJ, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7: 195–200, 1995Google Scholar
- 18.McCully KS: Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Labo Sci 24: 27–59, 1994Google Scholar
- 46.Eberhardt RT, Forgione MA, Cao A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Glodshmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J: Endothelial dysfunction in a murine model of mild hyperhomocysteinemia. J Clin Invest 106: 483–491, 2000PubMedGoogle Scholar
- 49.Stamler JS, Loscalzo J: Endothelium derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovasc Pharmacol 20: 202–204, 1992Google Scholar
- 50.Grow AJ, Cobb F, and Stamler JS: Homocysteine, nitric oxide and nitrosothiols. In: Homocysteine in health and disease, D Jacobsen, R Carmel (eds). Cambridge University Press, Cambridge, 2001 pp. 39–45Google Scholar
- 55.Jakubowski H, Zhang L, Bardeguez A, Aviv A: Homocysteine-thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Cir Res 87: 45–51, 2000Google Scholar
- 56.Wang G, Siow YL, O K: Homocysteine induces monocyte chemoattractant protein-1 expression by activation NF-kappa B in THP-1 macrophages. Am J Physiol Heart Circ Physiol 280: 2840–2847, 2001Google Scholar